<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03214133</url>
  </required_header>
  <id_info>
    <org_study_id>1020494</org_study_id>
    <nct_id>NCT03214133</nct_id>
  </id_info>
  <brief_title>Effects of Epicatechin-rich Cocoa on Collagen Synthesis</brief_title>
  <acronym>coca-dose</acronym>
  <official_title>Determining an Optimal Dose of Epicatechin-Rich Chocolate and Its Effect on Performance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the effects of dietary supplementation of epicatechin-rich cocoa&#xD;
      in humans on collagen synthesis and power-based performance outcomes (rate of force&#xD;
      development).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators have recently completed a study looking at the expression of the collagens&#xD;
      following consumption of increasing doses of epicatechin in rats . This data clearly shows&#xD;
      that increasing doses of epicatechin, either 0.5 mg.kg-1 delivered once, twice, or three&#xD;
      times a day, or 2 mg.kg-1 once a day, results in increasing expression of the fibrillar&#xD;
      collagens (I, III, and V). This preliminary data suggests that epicatechin-rich chocolate&#xD;
      supplementation can increase collagen expression in humans and that this may improve force&#xD;
      transfer. From this background, the hypothesis proposed is that supplementation with&#xD;
      epicatechin-rich chocolate will increase rate of force development and performance in&#xD;
      athletes. Therefore, this simple nutrition intervention has the potential to simultaneously&#xD;
      improve performance, decrease injuries and accelerate return to competition through improved&#xD;
      collagen synthesis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 23, 2017</start_date>
  <completion_date type="Actual">August 30, 2018</completion_date>
  <primary_completion_date type="Actual">August 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Arm 1 of the project will employ a randomized single-blinded crossover design with subjects completing all 4 of the epicatechin-rich chocolate trials (0, 1, 2 and 3 mg.kg-1). Arm 2 will use a randomized parallel double-blind design with neither the subjects nor the investigators knowing who is on which treatment (optimized epicatechin-rich chocolate dose or Dutch processed/epicatechin depleted placebo.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Alkalized (0.01 mg epicatechin/g) ) and non alkalized cocoa (4.1 mg epicatechin/g) will be mixed in various ratios to achieve the desired 0, 1, 2, 3 mg/ kg body mass but maintaining equally weighed dose of cocoa for each intervention.&#xD;
For Arm 2, the same quantity of either alkalized or non alkalized cocoa will be given to achieve the optimized dosed of epicatechin.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Epicatechin-rich cocoa dose response</measure>
    <time_frame>~26 days</time_frame>
    <description>investigating effects doses of 0, 1, 2, 3 mg epicatechin/kg/day procollagen type I N-terminal propeptide (PINP) in the blood after 5 days of supplementation with 2-day wash out between.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of the optimized dose of epicatechin-rich cocoa on performance</measure>
    <time_frame>~22 days</time_frame>
    <description>Performance measures (of rate of force development) will be quantified for 3 weeks alongside the ingestion of an optimized dose of epicatechin-rich cocoa vs placebo.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Collagen Synthesis</condition>
  <arm_group>
    <arm_group_label>Epicatechin Dose Response</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will investigate varying doses of epicatechin on procollagen type I N-terminal propeptide (PINP) at varying doses CON, 1, 2, 3 mg/kg body mass.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epicatechin-rich cocoa on performance</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Athletes will ingest the optimized dose of epicatechin-rich cocoa vs placebo alongside maximum power training to determine if this nutritional intervention results in a greater increase in RFD and performance than maximum power training alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Epicatechin-rich cocoa dose response</intervention_name>
    <description>Subjects consume randomized doses of 0, 1, 2, 3 mg epicatechin/kg from epicatechin-rich cocoa. The optimal dose of epicatechin-rich chocolate will be the dose which have the greatest increase PNIP levels.</description>
    <arm_group_label>Epicatechin Dose Response</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Epicatechin-rich cocoa vs placebo on performance</intervention_name>
    <description>An optimized dose of epicatechin-rich cocoa or placebo will be given for 3 weeks alongside a prescribed power-based training program. In a randomized parallel design the effect of the optimal dose of epicatechin-rich chocolate, compared to placebo, on maximal isometric squat force, RFD, and jump testing will be quantified.</description>
    <arm_group_label>Epicatechin-rich cocoa on performance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Collegiate level male athletes between the ages of 18Â¬-25 years of age, currently&#xD;
             participating in sport, will be recruited to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of more than 3 musculoskeletal injuries within the past 12 months.&#xD;
&#xD;
          -  Health and dietary restriction (e.g. lactose intolerance) that would be affected by&#xD;
             the supplementation protocol.&#xD;
&#xD;
          -  The initial phase will be performed in males since collagen synthesis varies&#xD;
             significantly throughout the menstrual cycle in females. Since collagen synthesis is&#xD;
             the main outcome measure for the study this would confound the initial phase of the&#xD;
             work. Provided this work proves successful then the investigators will aim to proceed&#xD;
             with similar research in females.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Baar, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurobiology, Physiology &amp; Behaviour</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 7, 2017</study_first_submitted>
  <study_first_submitted_qc>July 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The individual participant data will not be made available to other researchers. Any data shared will be published in a blinded manner.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

